Seoul Pharma Co. Ltd (KQ:018680) — Market Cap & Net Worth
Market Cap & Net Worth: Seoul Pharma Co. Ltd (018680)
Seoul Pharma Co. Ltd (KQ:018680) has a market capitalization of $15.37 Million (₩22.68 Billion) as of August 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25887 globally and #1932 in its home market, demonstrating a -7.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seoul Pharma Co. Ltd's stock price ₩1945.00 by its total outstanding shares 11659319 (11.66 Million). See Seoul Pharma Co. Ltd (018680) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Seoul Pharma Co. Ltd Market Cap History: 2015 to 2026
Seoul Pharma Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $119.28 Million to $15.37 Million (-17.90% CAGR).
Index Memberships
Seoul Pharma Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$206.59 Billion | 0.01% | #1040 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$206.59 Billion | 0.01% | #1040 of 1384 |
Weight: Seoul Pharma Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Seoul Pharma Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seoul Pharma Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Seoul Pharma Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Seoul Pharma Co. Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $119.28 Million | $44.73 Billion | -$783.06 Million | 0.00x | N/A |
| 2016 | $72.94 Million | $45.92 Billion | $816.80 Million | 0.00x | 0.09x |
| 2017 | $86.19 Million | $46.65 Billion | $881.44 Million | 0.00x | 0.10x |
| 2018 | $45.50 Million | $44.14 Billion | -$4.35 Billion | 0.00x | N/A |
| 2019 | $53.26 Million | $53.95 Billion | -$1.87 Billion | 0.00x | N/A |
| 2020 | $86.52 Million | $52.23 Billion | -$1.34 Billion | 0.00x | N/A |
| 2021 | $62.03 Million | $40.46 Billion | -$9.69 Billion | 0.00x | N/A |
| 2022 | $39.74 Million | $50.06 Billion | $855.09 Million | 0.00x | 0.05x |
| 2023 | $30.26 Million | $52.46 Billion | $3.52 Billion | 0.00x | 0.01x |
| 2024 | $26.15 Million | $53.58 Billion | $1.70 Billion | 0.00x | 0.02x |
Competitor Companies of 018680 by Market Capitalization
Companies near Seoul Pharma Co. Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Seoul Pharma Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Seoul Pharma Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Seoul Pharma Co. Ltd's market cap moved from $119.28 Million to $ 15.37 Million, with a yearly change of -17.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩15.37 Million | -36.85% |
| 2025 | ₩24.34 Million | -6.95% |
| 2024 | ₩26.15 Million | -13.58% |
| 2023 | ₩30.26 Million | -23.86% |
| 2022 | ₩39.74 Million | -35.92% |
| 2021 | ₩62.03 Million | -28.31% |
| 2020 | ₩86.52 Million | +62.46% |
| 2019 | ₩53.26 Million | +17.05% |
| 2018 | ₩45.50 Million | -47.21% |
| 2017 | ₩86.19 Million | +18.17% |
| 2016 | ₩72.94 Million | -38.85% |
| 2015 | ₩119.28 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Seoul Pharma Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.37 Million USD |
| MoneyControl | $15.37 Million USD |
| MarketWatch | $15.37 Million USD |
| marketcap.company | $15.37 Million USD |
| Reuters | $15.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more